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Accepted 27 November 2012AbstractSexual dysfunction refers to difficulties that occur during the sexual response cycle that prevent the individual from experiencing satisfaction
from sexual activity. It is relatively difficult to estimate the prevalence of female sexual dysfunction (FSD), because the definition and diagnostic
criteria are still controversial and under development. These difficulties reveal our insufficient understanding of the basis of FSD. This review
was conducted in an effort to deal with this complicated clinical issue, by examining the most updated clinical criteria of FSD under the context
of a redefined female sexual response model.
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Sexual dysfunction refers to a problem that occurs during
the sexual response cycle that prevents the individual from
experiencing satisfaction from sexual activity. It is relatively
difficult to estimate the prevalence of sexual dysfunction in
women [1] because the parameters of female sexual dys-
function (FSD) are not as clear as those of male sexual dys-
function (MSD). For example, the associated risk factors for
men are much clearer, including cardiovascular and/or neu-
rological diseases, endocrine disorders, aging, or drug abuse* Corresponding author. Department of Obstetrics and Gynecology, Taipei
Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
E-mail addresses: phwang@vghtpe.gov.tw, phwang@ym.edu.tw (P.-H.
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http://dx.doi.org/10.1016/j.tjog.2013.01.002[2]. Unlike MSD, the results after assessment of FSD are often
conflicted, partly because the means of assessing FSD have
varied widely from one study to another [3]. In addition, it is
more difficult to evaluate specific problems, such as arousal/
lubrication and orgasm; therefore, they are less commonly
reported. Furthermore, the assessment of sexual function in
women is frequently confounded by many factors, including
depressed mood and other comorbid medical and psychiatric
disorders [5]. Some have favored psychological factors as
a primary cause of FSD, rather than other pathophysiological
problems [6].
The success of sildenafil (one of the phosphodiesterase type 5
inhibitors) inMSD [7] has stimulated studies of similar drugs for
FSD, however, these drugs have shown little effect in women
[8,9]. Furthermore, while the term FSD has been used for many
years, the diagnosis and definition of FSD is still not acceptable
to all [3,4]. These situations and unmatched clinical needs gavecs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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diagnostic classification of FSD was proposed by a panel
meeting in 1998 [10,11].As a result, an initial understanding and
classification system was built to define this issue.
The four-phase sexual response model
To understand the normal sexual response, Masters and
Johnson described a model of four-phase sexual response,
consisting of excitement, plateau, orgasm, and resolution [12].
The sexual responses of both men and women begin in the
desire phase, which is modulated by a balance of the
dopamine-sensitive excitatory center and the serotonin-
sensitive inhibitory center in the brain [13]. Testosterone is
reported to respond to the modulating of the threshold of these
centers. The activation of these centers subsequently initiates
the downstream signals, which produce genital sexual re-
sponses through the spinal cord and the related reflex centers.
During the arousal phase, the parasympathetic nervous
system mediates the engorgement of vascular and genital
changes, including enlargement of the clitoris, dilation of
perivaginal arterioles, and expansion of the inner two-thirds of
the vaginal barrel (the tenting effect). Estrogen also regulates
the transudation across the vaginal mucosa and results in
vaginal lubrication [14,15].
The plateau phase is the continuation of the arousal phase.
Plateau refers to the level of sexual excitement, which has been
reached and is maintained for some time before reaching the
orgasmic phase. At the plateau phase, the length and width of
the inner two-thirds of the vagina expands, and the outer one-
third of the vagina becomes congested with blood (Fig. 1).
Defined by Masters and Johnson, the congested and tightening
vagina was thought to be a feature of an orgasmic platform [12].
A series of contractions of the related genital muscle groups
throughout the body occurs at the orgasmic phase. During the
orgasm, the heart rate, blood pressure, and respiratory rate
elevate. After the orgasmic phase, the body returns to the
unexcited state, which is called the refractory phase. It is noted
that the refractory period is not observed in some women, andFig. 1. Physiological changes in the current model of the female sexual respothey usually cannot respond to additional stimulation. How-
ever, in most cases, women can response to repeated simu-
lation, and reach second or third orgasm soon after the first.
Under the basic model established by Masters and Johnson
[12], sexologists have developed treatments for patients who fail
to respond to sexual stimuli. With the increasing understanding
of the sexual responses in women, the American Psychiatric
Associations’ Diagnostic and Statistical Manual of Mental
Disorders (DSM) further classifies sexual response into four
related but neurophysiologically independent phases: Phase I:
desire or libido; Phase II: arousal or excitement; Phase III:
orgasm or climax; and Phase IV: refractory or resolution. Based
on this four-phase class of female sexual response, the diag-
nostic and classification system was developed [16].
The 1998 diagnostic classification of FSD
A working definition of and classification for FSD was set
up in 1998 [17,18]. As outlined above, the sexual response
process is initiated with the desire phase, followed by the
arousal phase, and then the orgasm phase. It is considered that
sexual response follows the same linear pattern in men and
women. In spite of the fundamental model consisting of
similar factors, there are a few minor differences in the sexual
responses of men and women. It is thought that some of these
differences between men and women are biologically based,
and some are psychological based, resulting from general or
individual psychosocial conditions. However, for every indi-
vidual case, it is quite difficult to distinguish between the
biological and psychosocial factors. In an attempt to define
both the pathological and psychosocial aspects of FSD, the
1998 diagnostic classification of FSD was divided into four
discrete categories [17,18]:
(1) Hypoactive sexual desire disorder is characterized as
a lack or absence of desire for sexual activity for some
time. Hypoactive sexual desire disorder usually causes
distress that does not result from other mental disorder or
medical condition. However, it is usually associated withnse cycle. BP ¼ blood pressure; HR ¼ heart rate; RR ¼ respiratory rate.
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sexual desire may result from endocrine disorders.
(2) Sexual arousal disorder is characterized by the lack or
absence of desire for sexual activity with sexual stimula-
tions that normally induce sexual arousal, or the disability
to maintain sexual responses during sexual arousal. It
causes reduced genital sensation, and decreased vaginal
smooth muscle relaxation and lubrication. Sexual arousal
disorder probably results from the side effect of medica-
tions, pelvic diseases, neural disorders, or peripheral vas-
cular problems.
(3) Orgasmic disorder refers to the inability to reach
orgasm after adequate sexual arousal and stimulation.
Orgasmic disorder also causes personal distress, and
may be associated with neural disorders or spinal cord
injuries.
(4) Sexual pain disorder refers to pain in the pelvis or vagina
during any stage of normal sexual stage, including desire,
arousal, or orgasm. The subcategories of sexual pain dis-
order include dyspareunia and vaginismus. Dyspareunia is
characterized by pain in the pelvic area during or after
intercourse. Vaginismus is characterized by involuntary
spasm of the vagina-related musculature, which results in
a painful penetration. Sexual pain disorder is usually
associated with psychological trauma or physiological
pelvic diseases.
The debates on the controversial definition of FSD
Based on the 1998 definition, a 1999 study indicated that
43% of American women suffered from sexual dysfunction
[19]. In this study, women who experienced any of the fol-
lowing conditions were considered to have sexual dysfunction:
lack of sexual desire, difficulty in arousal, inability to reach
orgasm, pain during intercourse, failure to feel pleasure from
sex, or anxiety about sexual performance. However, the results
of this study were highly controversial [20e23]. The main
critiques included the absence of standard criteria to determine
if the conditions mentioned above affect the sexual quality of
life of the subjects, and a survey sample duration that was too
short (2 months), and in which the conditions of the subjects
may only represent a temporary response to other personal
distress.
Several studies used physiological measurements to
examine the effects of sildenafil on women with female sexual
arousal disorder. However, it has been suggested that there is
a role for medical interventions in FSD, but not in isolation
from psychological factors [20,21]. Tiefer et al defined FSD as
discontent or dissatisfaction with any emotional, physical, or
relational aspect of the sexual experience [22]. It may be
caused by sociocultural, relationship-related, psychological, or
medical factors [23]. Nonetheless, a study from the Kinsey
Institute has further indicated that emotional health and per-
sonal relationship factors were more important for women’s
sexual satisfaction than the experience of, and ability to,
achieve orgasm [24]. These debates revealed the fact that the
definition of FSD was mostly focused on physical problems,which is partly based on the previous understanding of male
and female sexual responses. The measurement of sexual
problems in men has focused mostly on erections, which are
easily identified and quantified. By contrast, female sexual
problems are much more difficult to qualify or quantify. To
counter these difficulties, clinicians and researchers recom-
mended a more comprehensive evaluation, including physical
and psychosocial factors. Furthermore, studies also suggested
that rather than using the four-phase linear model of sexual
response, a more comprehensive female sexual response cycle
should be introduced to describe the complex physical and
sociopsychological factors involved in female sexual behavior
[13].
Current model of female sexual response
The latest studies have suggested that the female sexual
response cycle is fundamentally different from the linear
model, consisting of independent phases, used by Masters and
Johnson [12]. The female sexual response cycle comprises
overlapping phases in a variable sequence, and may be influ-
enced by various psychological and physical factors during the
process. Under this model, sexual motivation is much more
complicated than simply the presence or absence of sexual
desire. For example, women may respond to multiple factors
for the initiation of sexual activity. Fig. 1 presents this new
model of the female sexual response cycle containing physi-
cal, psychological, and emotional factors. The initiation of
a female sexual response may be initiated spontaneously by
simple innate sexual desire. This type of desire is reported to
be associated with the menstrual cycle and may decrease with
age [25,26]. In another aspect, it may also initiate from the
desire for emotionally intimate, for example, to feel being
needed or having emotional well-being. These emotions lead
to the instigation of a woman’s sexual activity and increase her
willingness to focus on sexual stimuli. With an appropriate
environmental context, the sexual stimuli can then result in
subjective sexual arousal under biological and psychological
processing. The stimuli increase sexual excitement and trigger
the desire for sex. Proper sexual stimuli can result in non-
sexual rewards, which drive and further enhance the will to
have sex. As a result, both the emotional and physical feed-
backs enhance the motivation and the intensity of sexual
stimuli, which finally results in sexual satisfaction. This new
model suggests that sexual arousal in women is not only
affected by the objective extent of sexual excitement but also
by subjective emotions, which implies that the correlation seen
in men between arousal and erection is not applicable to
women.
The redefined definition
The new model of female sexual response cycle provides
new insight into the issue. It raises several questions regarding
the definitions and treatment guidelines of FSD. For example,
previous definitions of FSD proposed that the sexual response
in a woman is exclusively initiated by the innate, obvious
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absence of an obvious sexual desire was an evidence of FSD.
Nonetheless, previous definition of arousal disorder focuses
mainly on physical measurements such as vaginal lubrication
and swelling response. However, studies have shown that there
is a poor correlation between genital excitement and subjective
arousal in response to sexual stimuli in women [27,28].
The original 1998 version of the diagnostic classification of
FSD was based on the understanding of a linear model of
female sexual response [18]. It was considered that the sexual
response followed essentially the same pattern in both sexes.
However, current studies have suggested that there are more
differences between males and females in their sexual
response models. To address this issue, the International
Consensus Conferences on FSD have renewed a working
definition of FSD, including both physiological and psycho-
logical symptoms, as a revision of the clinical definition of
FSD [18]. The panel built the definitions of sexual dysfunction
on the basis of the World Health Organization’s International
Classification of Diseases (ICD-10) and the American Psy-
chiatric Association’s Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) [18]. The ICD-10 focuses on the
physical factors involved in this disorder, and the DSM-IV
addresses the psychological factors that affect the normal
sexual response.
The classification of FSD was further revised by the Second
International Consensus of Sexual Medicine in 2004 [29]. The
2004 version established guidelines to examine the extent of
the distress caused by sexual dysfunction, which allowed
physicians to evaluate the clinical significance of the symp-
toms and further define the distress. Under the revised
guidelines, physicians can identify the underlying problem
through helping the patient to reconstruct her sexual response
factors by evaluating multiple factors that may contribute to
sexual dysfunction including side effects of medications, gy-
necological diseases, and even psychosocial factors such as the
patient’s social life context.
Current opinion on the treatment of FSD
The new models and revised guidelines of the sexual
response cycle in females imply the complex nature of FSD,
which consists of both biological problems and psychosocial
conditions [30]. The current opinion on the treatment of FSD
further suggests that, under certain cultural circumstances,
a tendency toward sexual inhibition of women could be
a result of sociocultural effect [31]. Women who are under
psychosocial restrictions in certain cultural contexts may be
asked to inhibit their sexual desire and restrain their sexual
experiences. Such psychosocial contexts inhibit the normal
sexual function. As a consequence, it is difficult to distinguish
whether the causes of FSD are biologically or psychosocially
based. In such cases, education should also be introduced by
the physicians for both the patients and their partners. While
most patients still consider that a normal sexual ability means
the conventional staged physical responses including desire,
arousal, and orgasm, patients and their partners could beeducated that individual sexual responses vary widely and
both emotional intimacy and physical sexual activity are
contributing factors.
The DSM-IV is now under revision by the American Psy-
chiatric Association, and the DSM-V will be released and
adopted by 2014 [11]. Several important changes regarding the
diagnostic criteria of FSD are being made in this revision [32].
The classification of female sexual desire disorder will be
removed, and the classification of female arousal disorder will
be revised as female interest/arousal disorder. Moreover, the
classification of vaginismus will be replaced with penetration
disorder, and dyspareunia will be revised to genital pelvic pain.
The changes highlight an important dilemma that it is
difficult to define abnormal female sexual desire. In many
cases, females were reported to live with a low level of sexual
desire/libido without any distress. While there are psychoso-
cial factors involved, determining whether there is a standard
to define the quality or quantity of female sexual desire in each
individual case is difficult. For example, a woman who has
a low frequency of sexual activity, yet reports an average
extent of satisfaction with her sex life, is rarely diagnosed as
having sexual desire disorder; rather than defining a “disor-
der”, it is more important to evaluate the quality of the pa-
tient’s sexual life, and take that into consideration. The revised
model of the female sexual response cycle has addressed the
importance of psychological factors as nonsexual rewards that
drive the sexual response, including emotional intimacy, well-
being, lack of negative effects from sexual avoidance, etc. The
model offers a strong basis to justify the new diagnostic cri-
teria in the DSM-V.
The new model further implies new concepts of female
sexual responses. Currently, there are no standard means to
quantify or qualify the extent of sexual desire. The appearance
of sexual desire in individual cases varies, and sometimes
leads to the observation that the patient may be normally
aroused, yet with an apparently very low level of sexual desire.
Also, in the revised model, the occurrence of desire and
arousal are not sequentially defined. Sexual arousal can be
enhanced by sexual desire, and vice versa. The apparent
expression of sexual desire may be relatively low, yet it can be
aroused in individual cases. This leads to the misinterpretation
that the responses to sexual desire and arousal are discrete. As
a result, in the upcoming DSM-V, the classification of female
sexual desire disorder will be removed and revised as female
interest/arousal disorder, which covers a more varied expres-
sion of sexual desire in females. At present, it is clear that the
conventional four-phase linear model is not capable of cov-
ering the wide variation in female sexual response.
Conclusion
Along with the understanding of female sexual response,
we know that the sexual response of females is not the same as
that of males, which is a linear desire/arousal/orgasm process.
This implies that a more comprehensive guideline for the
treatment of FSD is still needed. To ignore the complexity of
the female sexual response may lead to an incorrect diagnosis
7C.-H. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 3e7because of individual difference as well as complicated so-
ciopsychological factors. The current treatment guideline for
FSD is being reviewed and many efforts are still needed to
deal with this complicated issue if we exclude organic lesions
[33].
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